ARTICLE | Product Development
Vaccines from CureVac, Imperial enter the clinic as PDS finds a partner for its product
The WHO halted, for a second time, the hydroxychloroquine arm of its SOLIDARITY trial
June 18, 2020 1:11 AM UTC
CureVac and Imperial announced trial starts for their COVID-19 vaccines this week. A third vaccine, from PDS Biotech and Farmacore, is expected to start a Brazilian Phase I trial.
The trial starts come as the European Commission launches an EU-wide procurement strategy to ensure equitable access to COVID-19 vaccines on the continent. The commitment aims to meet European demand before making vaccines available globally (see “EU Lays Out Strategy”)...